A clinicopathological study of multidrug therapy in borderline tuberculoid leprosy.
J Indian Med Assoc
; 92(10): 336-7, 1994 Oct.
Article
em En
| MEDLINE
| ID: mdl-7822849
ABSTRACT
A study was undertaken to evaluate the efficacy of multidrug therapy as per WHO recommendation in 50 fresh cases (46 males and 4 females) suffering from borderline tuberculoid leprosy. All were given multidrug therapy consisting of rifampicin 600 mg once a month and dapsone 100 mg daily for 6 months. At the end of 6 months all were evaluated clinically and histopathological examinations of the lesions were studied. The lesions were still active in 60% of patients clinically; 32% cases receiving multidrug therapy had shown marked improvement. Histologically lymphocytic infiltration in skin still persisted in all the slides examined and nerve infiltration was still present in 68% of cases at the end of 6 months after receiving multidrug therapy. The study shows that treatment with multidrug regimen for 6 months may not be sufficient to treat borderline tuberculoid leprosy cases.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Rifampina
/
Hanseníase Dimorfa
/
Hanseníase Tuberculoide
/
Dapsona
Tipo de estudo:
Guideline
/
Observational_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Indian Med Assoc
Ano de publicação:
1994
Tipo de documento:
Article